The model for healthcare delivery and treatment was upended by the COVID-19 pandemic, as ordinary Americans have learned to take more control of their own care and treatment, harnessing a new class of technology tools that have given individuals unprecedented clout. But patients and healthcare providers still need to partner together for the best outcomes, according to Jim Weiss, founder and CEO of Real Chemistry.
As the U.S. moves from managing COVID-19 to managing a recovery, it is clear that the pandemic lockdowns had a profound impact on how people consume media, how they receive healthcare information, and their expectations changed around how brands connect with them. For marketers, building brand value with customers will be tantamount to marketing success in this brave new world.
Roger Perlmutter will helm the drug discovery startup Eikon Therapeutics after the industry veteran and former president of Merck Research Laboratories departed the pharma giant at the end of 2020. California-based Eikon emerged from stealth mode with a $148 million Series A financing round.
More than 60 U.S. stadiums and other venues are deploying an app from Clear to verify people’s Covid-19 status, placing the New York company known for its airport security fast lanes at the forefront of a national debate over “vaccine passports.”
Acting FDA Commissioner Janet Woodcock shared her thoughts on pandemic issues and outlined FDA modernization plans in a Q&A session with the Alliance for a Stronger FDA..
Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
Medicago said on March 16 the Canadian drug developer had started a late-stage study of the company’s experimental Covid-19 vaccine combined with an adjuvant from GlaxoSmithKline.
2021’s crystal ball: Six AI predictions from Aktana management that will shape a new commercial model.
France-based Servier and U.K.-based MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases
Stephen Byers, Ph.D., associate director and professor of oncology at Georgetown Lombardi, and his team published a paper in the journal Gastroenterology regarding their findings of a novel target for pancreatic cancer therapy.